GOODBODY HEALTH LTD - GDBYF STOCK NEWS

Goodbody Health Limited has partnered with Datar Cancer Genetics to introduce the Trucheck multi-cancer screening solution in the UK. This liquid biopsy technology utilizes Circulating Tumor Cells (CTCs) for early cancer detection, supported by over 40,000 individuals. The partnership aims to enhance participation in cancer screening, ultimately promoting preventative healthcare. Executive Director Dr. Vineet Datta emphasized that early detection through screening can significantly improve treatment outcomes. CEO George Thomas expressed excitement about this innovation and its integration into Goodbody's health offerings.

Goodbody Health Limited (AQSE:GDBY)(OTCQB:GDBYF) announced significant board changes effective January 1, 2023. Geremy Thomas will step down from his executive role but remain as Non-Executive Chairman. Anne Tew is departing as Chief Financial Officer and Director but will continue as Company Secretary and support the CFO transition. CEO George Thomas expressed gratitude for their contributions and noted their ongoing support of the company's strategic direction into 2023.

Goodbody Health Limited (AQSE:GDBY)(OTCQB:GDBYF) announced the divestment of its Polish CBD operations to Voyager Life PLC for £1.5 million, consisting of £0.5 million in cash and £1.0 million in convertible loan notes (CLNs). The deal includes the sale of the Sativa Wellness Poland and Olimax NT companies, with Voyager taking operational control on January 1, 2023. Goodbody plans to use the proceeds to enhance its health and wellness sector, which contributed over 90% of its revenue in 2021. This strategic move is aimed at reducing costs associated with underperforming CBD operations.

Goodbody Health Limited (AQSE:GDBY)(OTCQB:GDBYF) has announced the resignation of Marc Howells as Chief Executive Officer and from the Board, effective immediately. The company expressed gratitude for his contribution. George Thomas, an existing Executive Director and Managing Director of Goodbody Wellness, has been appointed as the new CEO. Geremy Thomas, Executive Chairman, expressed optimism about the company’s future under George's leadership, citing his successful management of the clinic business for over two years.

Goodbody Health Limited (AQSE:GDBY)(OTCQB:GDBYF) revealed its Q3 2022 financial results, reporting revenue of £9.29 million, a 6% decline compared to 2021. The net comprehensive loss increased to £1.67 million, up £0.8 million year-on-year. This decline is attributed to reduced COVID testing and expected lower annual outcomes amid economic pressures. The company is focusing on preventative diagnostics and has streamlined its operations, including a strategic shift to Guernsey and cost reductions. The total number of clinics providing health services has reached 258.

Goodbody Health Limited (AQSE:GDBY)(OTCQB:GDBYF) announced a partnership with Allied Pharmacies Limited to expand its clinic network by adding 17 pharmacies. These clinics will offer diagnostic testing and earwax removal services, addressing the needs of the 2.3 million patients in the UK who require such care annually. The painless procedure will benefit patients by providing convenient access through local pharmacies, enhancing overall wellbeing. CEO Marc Howells expressed optimism about increased customer footfall and improved health outcomes.

Goodbody Health Limited (AQSE:GDBY)(OTCQB:GDBYF) has signed a distribution agreement with Tasso Inc to enhance its UK pharmacy and wellness offerings. Tasso's innovative, needle-free blood collection devices will enable more comprehensive testing at Goodbody clinics and by healthcare professionals. The rollout is expected later this year, expanding patient-friendly options for health monitoring. Goodbody has also launched 100 home testing stands for consumer convenience. CEO Marc Howells highlights this contract as a major industry breakthrough.

Goodbody Health Limited (AQSE:GDBY) announced the transfer of 200,000 ordinary shares by Executive Chairman Geremy Thomas to an unrelated party for nil consideration on August 30, 2022. Following this transaction, Thomas holds 7,640,638 ordinary shares, representing approximately 20.94% of the company's issued share capital. The company emphasizes that forward-looking statements made in the release are subject to significant risks and uncertainties, which may materially affect future results.

Goodbody Health Limited (AQSE:GDBY) announces its successful continuation to Guernsey as of August 19, 2022, transitioning from Goodbody Health Inc. The company voluntarily delisted from the CSE on August 17, 2022, with a ten-for-one share consolidation effective August 18, 2022. Following these changes, Goodbody will have 36,496,276 Ordinary Shares outstanding and anticipates resuming trading on AQSE on August 24, 2022. Executive Chairman Geremy Thomas highlighted the move as a strategy to focus on the London market and growth in the diagnostic testing sector.